Avian ("Bird") Flu Stocks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avian ("Bird") Flu Stocks

NNVC 1.685

+0.3%

3:55 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Allan Harris	2/15/2006 12:08:45 PM
	of 428

Novavax Inc. entered a collaborative research agreement with the University of Pittsburgh School of Medicine Wednesday to evaluate the efficacy of "virus-like particle" influenza vaccines. Under the agreement, the school and Novavax (NASDAQ:NVAX - News) will evaluate the full range of immunity from experimental Novavax vaccines. In addition, scientists will evaluate the use of Novasomes -- the company's patented and proprietary structures in which drugs can be encapsulated for topical or oral delivery -- to augment or broaden the immune response from vaccines. The principal investigators for the agreement are Rick A. Bright, vice president of vaccine research at Novavax of Malvern, Pa., and Ted M. Ross, a researcher from the medical school. Published February 15, 2006 by the Philadelphia Business Journal

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next